Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

Figure 2

Classification of patients with PDAC vs. patients with benign disease. (A) Feature finding results showing the percentage occurrence of cytokines in models following resampling of training data for PDAC vs. benign disease. (B) Training set ROC Curves for PDAC vs. benign disease for a panel of IL-8, IP-10, IL-6, PDGF and CA19-9 versus CA19-9 alone. (C) Test set ROC curves for PDAC vs. benign disease for the panel of IL-8, IP-10, IL-6, PDGF versus CA19-9. (D) The resampling performance of the panel of IL-8, IP-10, IL-6, PDGF and CA19-9 versus CA19-9 for the classification of PDAC vs. benign disease. The accuracies, sensitivities and specificities of the panel compared to CA19-9 alone over 100 patient-balanced resamples is shown. The quantiles of the performance indicators are summarised as boxplots with individual points superimposed and the significance of Friedman test comparisons is indicated (***p < < 0.001).

Back to article page